Skip to main content
    N

    Nuvectis Pharma Inc (NVCT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $18.93
    +0.93 (+5.17%)

    Market Cap: $592.49M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    37%(7/19)
    Avg Surprise
    -13.42%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.24
    Range$-0.28 - $-0.21
    6 analysts
    EPS Revisions
    1
    0
    7d
    3
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.26+8.4%
    60d ago$-0.25+1.7%
    30d ago$-0.23-4.3%
    7d ago$-0.240.0%
    Current$-0.24
    Revenue Consensus
    $0
    Range$0 - $0
    6 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.23
    Range$-0.35 - $-0.12
    6 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.23---
    Sep 26EST
    		-$-0.24---
    Jun 26
    Reported Aug 4
    		$-0.30$-0.25-20.00%Miss+0.0%
    Mar 26
    Reported May 5
    		$-0.26$-0.31+16.13%Beat+3.7%
    Dec 25
    Reported Feb 11
    		$-0.31$-0.31+0.00%Beat+11.4%
    Sep 25
    Reported Nov 4
    		$-0.44$-0.25-76.00%Miss-83.3%
    Jun 25
    Reported Aug 5
    		$-0.30$-0.25-20.00%Miss-15.4%
    Mar 25
    Reported May 6
    		$-0.27$-0.25-8.00%Miss-8.0%
    Dec 24
    Reported Feb 25
    		$-0.35$-0.26-36.35%Miss+14.6%
    Sep 24
    Reported Nov 5
    		$-0.24$-0.25+4.00%Beat+35.1%
    Jun 24
    Reported Aug 6
    		$-0.26$-0.31+16.13%Beat+31.6%
    Mar 24
    Reported May 7
    		$-0.25$-0.39+35.90%Beat+7.4%
    Dec 23
    Reported Mar 5
    		$-0.41$-0.36-13.89%Miss+16.3%
    Sep 23
    Reported Nov 8
    		$-0.37$-0.34-8.82%Miss+11.9%
    Jun 23
    Reported Aug 9
    		$-0.38$-0.21-80.95%Miss-35.7%
    Mar 23
    Reported May 10
    		$-0.27$-0.45+40.00%Beat+15.6%
    Dec 22
    Reported Mar 7
    		$-0.49$-0.38-28.95%Miss-2.1%
    Sep 22
    Reported Nov 8
    		$-0.42$-0.27-55.56%Miss+98.3%
    Jun 22
    Reported Aug 5
    		$-0.28$-0.24-16.67%Miss-
    Mar 22
    Reported May 10
    		$-0.32$-0.22-45.45%Miss-
    Dec 21
    Reported Jan 14
    		$-0.48$-0.85+43.53%Beat-
    Sep 21
    Reported Oct 21
    		$-24.43$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-14.45EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-214.60%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio1.68xQuick Ratio1.68x
    Trading Statistics
    Beta-0.24Avg Volume209.99K
    52-Week High$29.2752-Week Low$5.55

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$19.96
    SMA 20$20.64
    SMA 50$21.62
    SMA 200$14.01
    EMA 10$19.65
    EMA 20$20.42
    EMA 50$20.69
    EMA 200$15.70

    MACD

    Line: -0.84Signal: -0.57Hist: -0.26

    ADX

    ADX: 19.0+DI: 15.3-DI: 22.6

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down96.0
    PSAR$20.83

    Bollinger Bands

    Upper Band$23.19
    Lower Band$18.08
    %B Position2477%(Upper)
    Band Width0.17

    RSI (14-Day)

    Neutral
    41.4

    Momentum Oscillators

    Stoch %K12.6
    Stoch %D11.4
    Williams %R-72.6
    ROC (10d)-8.6%
    Momentum-1.79
    CCI (20d)-138.2
    MFI (14d)45.3

    Volatility Measures

    ATR (14d)$1.48(7.8%)
    StdDev (20d)1.28
    Hist Vol73.5%(High)

    Volume Flow

    VWAP$18.94
    OBV-2.8M
    AD Line-2.3M
    CMF (20d)-0.076

    Volume Metrics

    Avg Vol (20d)212.1K
    Vol Ratio0.7x
    VWMA (20d)$20.85

    Pivot Points

    R3$19.63
    R2$19.17
    R1$18.59
    Pivot Point$18.13
    S1$17.55
    S2$17.09
    S3$16.51

    Advanced Oscillators

    TSI-15.47
    Ultimate Osc43.2
    KST-108.59

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$26.80M$0$0$0$-4,101,000$0
    Cost of Revenue$0$0N/A$0$0$0$13.40M$0$0$0$10.97M$0
    Gross Profit$0$0N/A$0$0$0$13.40M$0$0$0$-15,068,000$0
    Operating Expenses$7.20M$6.26M$7.62M$7.79M$6.59M$5.57M$6.45M$4.36M$4.64M$4.40M$6.87M$6.16M
    R&D$4.68M$4.11M$5.09M$5.77M$3.61M$3.68M$4.50M$2.82M$2.94M$2.66M$4.26M$4.49M
    SG&A$2.51M$2.15M$2.53M$2.02M$2.98M$1.89M$1.95M$1.54M$1.70M$1.74M$2.60M$1.67M
    Operating Income$-7,197,000$-6,260,000$-7,617,000$-7,794,000$-6,595,000$-5,568,000$-6,449,000$-4,359,000$-4,643,000$-4,396,000$-6,866,000$-6,158,000
    Interest Income$0$0$0$332,000$0$0$0$206,000$0$0$0$277,000
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-7,020,000$-6,050,000$-7,314,000$-7,462,000$-6,334,000$-5,332,000$-6,248,000$-4,153,000$-4,428,000$-4,171,000$-6,622,000$-5,881,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-7,020,000$-6,050,000$-7,314,000$-7,462,000$-6,334,000$-5,332,000$-6,248,000$-4,153,000$-4,428,000$-4,171,000$-6,622,000$-5,881,000
    EBITDA$-7,020,000$-6,050,000$-7,617,000$-7,794,000$-6,334,000$-5,332,000$-6,449,000$-4,359,000$-4,428,000$-4,171,000$-6,866,000$-6,158,000
    EBIT$-7,020,000$-6,050,000$-7,617,000$-7,794,000$-6,334,000$-5,332,000$-6,449,000$-4,359,000$-4,428,000$-4,171,000$-6,866,000$-6,158,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about NVCT

    News

    Nuvectis Pharma Inc (NVCT-Q) Stock Price and News

    This article provides current stock price and news updates for Nuvectis Pharma Inc. (NVCT-Q). It includes financial data, analyst insights...

    The Globe and Mail•10/11/26•Somewhat-Bullish

    Nuvectis Pharma to present at Maxim Growth Summit 2026 on immunology and oncology therapies

    Nuvectis Pharma, a clinical-stage biopharmaceutical company, is set to present at the Maxim Growth Summit 2026 in New York on October 14. CEO Ron Bentsur will discuss the company's progress in developing immunology...

    Pluang•10/9/26•Somewhat-Bullish

    Nuvectis Pharma to Participate in the Maxim Growth Summit 2026

    Nuvectis Pharma, Inc. announced that its senior management will participate in the Maxim Growth Summit 2026 in New York. Ron Bentsur, Chairman and CEO...

    GlobeNewswire•10/9/26•Somewhat-Bullish

    Nuvectis Pharma Earns Breakthrough Therapy Status in China for Brain Cancer Treatment NXP200

    Nuvectis Pharma has received Breakthrough Therapy Designation in China for its brain cancer drug NXP200, targeting BRAF V600-mutant high-grade glioma. The designation, granted to partner Haisco Pharmaceutical Group...

    Kalkine Media•9/25/26•Bullish

    Nuvestis' In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It's Not Even Their Lead Asset

    Nuvectis Pharma's in-licensed cancer drug, NXP200, has received Breakthrough Therapy Designation in China for BRAF V600-mutant high-grade glioma...

    Benzinga•9/25/26•Bullish

    NVCT Valuation and Fair Value

    P/E
    -14.5x
    P/B
    48.9x
    See GNG's fair value

    NVCT Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -214.6%

    NVCT Competitors

    CompanyTicker
    Weave Communications IncWEAV
    Climb Bio IncCLYM
    Ironwood Pharmaceuticals IncIRWD
    Solid Biosciences LLCSLDB
    Olema Pharmaceuticals IncOLMA
    Fulgent Genetics IncFLGT
    Phathom Pharmaceuticals IncPHAT
    CorMedix IncCRMD

    Sector: Healthcare

    NVCT Analyst Ratings

    Consensus
    Buy
    Analysts
    5
    Strong Buy
    2
    Buy
    3
    Hold
    0
    Sell
    0
    Strong Sell
    0

    NVCT Bull Case vs Bear Case

    Bull case

    • 100.0% of NVCT's analyst ratings are Buy or Strong Buy.

    Bear case

    • NVCT beat EPS estimates in 25.0% of its last 8 reported quarters.

    NVCT Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    -17.5%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.24
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    3 up, 0 down

    Frequently Asked Questions About NVCT

    Does NVCT pay dividends?

    Nuvectis Pharma Inc (NVCT) does not currently pay a regular dividend.

    What is NVCT's market cap?

    Nuvectis Pharma Inc (NVCT) has a market capitalization of $592.49M with a current stock price of $18.93.

    Related stocks

    Sector: Healthcare

    All stocks starting with N

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In